TheranosA CAMP case study.

01. The CAMP Framework

A. The Four Pillars

The CAMP Matrix evaluates startup potential through four interconnected dimensions:

B. The 2x2 Matrix

The pillars combine into two composite dimensions:

• Internal Engine (Y-axis) = Capital + People, measures organizational capability
• External Promise (X-axis) = Advantage + Market, measures opportunity attractiveness

C. Stage-Aware Weighting

D. Scoring Rubric

02. Company History and Context

A. Founding Story

Elizabeth Holmes founded Theranos (originally "Real-Time Cures") in 2003 at age 19, after dropping out of Stanford University's chemical engineering program. Her stated vision was revolutionary: a world where anyone could get hundreds of blood tests from a single finger-prick, instantly, cheaply, and without visiting a lab. She claimed her technology would "democratize diagnostics" and save millions of lives through early disease detection.

B. Complete Funding History

C. Notable Investors and Board Members

The investor and board composition reveals a critical CAMP insight: Theranos deliberately recruited political figures rather than scientific or medical experts-a major governance red flag.

D. Key Partnerships (Built on Fraud)

03. Peak Assessment: Theranos at $9B Valuation (October 2014)

A. Apparent vs. Actual CAMP Scores

This section reveals the "fraud gap"-the difference between what investors saw and what actually existed.

Capital: 80/100 (Appeared Strong)

Capital Rationale: The capital was real-investors did transfer $1.4 billion. However, this capital was obtained through fraudulent misrepresentations about technology efficacy. The framework limitation: Capital pillar measures capital presence, not how it was obtained.

Advantage: 85/100 (Claimed) -> 0/100 (Actual)

Market: 75/100 (Real Opportunity Existed)

Market Rationale: The market opportunity was genuine. Consumers genuinely wanted faster, cheaper, less painful blood testing. The demand existed-but the technology to fulfill it did not.

People: 70/100 (Perceived) -> 10/100 (Actual)

B. CAMP Score Comparison: Apparent vs. Actual

04. The Collapse: A Detailed Timeline

A. Warning Signs Ignored (2012-2015)

B. The Unraveling (2015-2018)

C. Criminal Proceedings (2019-2023)

05. Matrix Journey Visualization

06. Key Lessons for the CAMP Framework

A. Framework Limitations

1. No Framework Defeats Active Fraud. If a founder fabricates core data (technology efficacy, clinical results), any assessment framework will fail. CAMP relies on disclosed information being truthful. When the Advantage pillar is based on lies, the score is meaningless.

2. People Pillar Governance Must Include Independent Validation. Theranos's People pillar appeared strong (famous founder, prestigious board). But the governance sub-factors-board expertise, scientific oversight, whistleblower treatment-would have scored 10-20/100 under rigorous assessment. Future CAMP applications should mandate governance deep-dives for biotech/deep-tech companies.

3. "Claimed but Unverified Advantage" Category Needed. For deep-tech companies, the framework should distinguish between verified advantages (peer-reviewed, FDA-approved) and claimed advantages (company assertions only). Theranos refused independent validation-a red flag that would lower Advantage to "Unverified" status.

B. Red Flags That CAMP Would Catch (With Proper Governance Assessment)

1. Board Without Domain Expertise: Politicians and generals, not scientists or medical executives-Governance sub-score: 15/100
2. Extreme Secrecy: Refusal to publish peer-reviewed data, blocked due diligence-Transparency sub-score: 10/100
3. Whistleblower Suppression: Threatened employees, hired private investigators to follow critics-Culture sub-score: 5/100
4. Nepotism in Leadership: COO (Sunny Balwani) was founder's boyfriend with zero biotech experience-Leadership sub-score: 20/100
5. Regulatory Avoidance: Classified tests as "wellness" to avoid FDA oversight-Advantage validation: Failed

C. Investor Due Diligence Failures

Notable investors like Rupert Murdoch ($125M), the DeVos family ($100M), and Partner Fund Management ($96M) failed to conduct basic due diligence:

• No independent technology validation was requested or performed
• No clinical trial data was reviewed (it didn't exist)
• Board composition was not scrutinized for domain expertise
• Investor checks relied on Holmes's personal charisma and famous board members
• FOMO (fear of missing out) on "the next big thing" overrode skepticism

07. Verified Factual Data and Sources

A. Company Information

• Founded: 2003 by Elizabeth Holmes (Stanford dropout) - Wikipedia, Britannica
• Original Name: Real-Time Cures, rebranded Theranos 2004 - SEC filings
• Total Funding: $1.4 billion+ across 19+ rounds - Tracxn, CrunchBase, SEC
• Peak Valuation: $9 billion (October 2014) - Forbes, Investopedia, WSJ
• Peak Employees: ~800 (2015) - Wikipedia, "Bad Blood" book

B. Key Dates

• WSJ Investigation: October 15, 2015 (John Carreyrou) - WSJ archives
• CMS "Patient Health Threat": January 2016 - CMS official records
• Walgreens Termination: June 2016 - Press releases, court filings
• SEC Charges: March 14, 2018 - SEC official announcement
• Federal Indictment: June 15, 2018 - DOJ records
• Dissolution: September 2018 - Delaware corporate records

C. Criminal Proceedings

• Holmes Conviction: January 3, 2022; 4 counts (3 wire fraud, 1 conspiracy) - DOJ, Reuters
• Holmes Sentence: 11 years, 3 months (November 18, 2022) - AP, DOJ
• Balwani Conviction: July 2022; 12 counts - DOJ
• Balwani Sentence: 12 years, 11 months - DOJ
• Holmes Prison Start: May 30, 2023 (FPC Bryan, Texas) - BOP, news reports

D. Key Resources

• Carreyrou, John. Bad Blood: Secrets and Lies in a Silicon Valley Startup (2018)
• Wall Street Journal investigation series (2015-2018)
• HBO documentary: The Inventor: Out for Blood in Silicon Valley (2019)
• Hulu series: The Dropout (2022)
• SEC enforcement action records (2018)
• DOJ criminal case documents (2018-2023)

E. Methodology Notes

• Framework Limitation: This case highlights that CAMP (like all frameworks) cannot detect intentional fraud. Scores assume truthful disclosure.
• Governance Enhancement: Post-Theranos, the framework recommends mandatory governance deep-dives for biotech, including board expertise analysis and independent validation requirements.
• Hindsight Bias: We acknowledge that identifying fraud is easier in retrospect. However, the red flags documented here were visible to contemporaneous observers who chose to ignore them.

08. Founder Actions and Metrics (Observed)